Baxter Healthcare’s Transformative Product Innovation Evolves the Healthcare Ecosystem

These were developed to extend aid to Hong Kong healthcare providers.

The constantly developing environment in the healthcare sector has been a top priority for many institutions in the past months, amplified by the new variants of COVID-19 coming in. As healthcare providers (HCPs) ramp up efforts to attend to more patients as possible, the need for improved products has also been the main concern for healthcare companies.

Baxter Healthcare recognises that Hong Kong HCPs are facing challenges with insufficient manpower and increasing treatment demand and complexity, a situation worsened with the extra burden caused by COVID-19.

Based on their market research, they have identified the needs from HCPs: to simplify treatment operations, to improve treatment safety, and to enhance accuracy in treatments.

As solutions to address these concerns, Baxter Healthcare introduced PrisMax, Evo IQ, and Starling. These three new products were developed based on HCPs’ needs for medical devices to enhance simplicity, safety, and accuracy.

The PrisMax is a next-generation Continuous Renal Replacement Therapy (CRRT) machine. It simplifies the complexities during CRRT and features an advanced user interface and unique auto-effluent drain accessory.

It helps ease the operations through its automatic draining of effluent fluid, which reduces bag changes by 60% and saves 30 minutes nursing time per day1.

The Evo IQ is a smart infusion system, that aimed at enhancing patient safety during medication administration.  It was developed based on 9 Global Human Factor studies and with over 225 hours of hands-on clinical feedback by critical care and anesthesia specialists2. It also features a dose error reduction system, Dose IQ, which can help ensure that the right dosing is delivered to patients.

The Starling is a non-invasive fluid responsiveness monitor which helps clinicians provide individualised fluid therapy based on accurate measurements.

Studies show that only 50% of hemodynamically unstable patients are responsive to IV fluid3. With 94% sensitivity and 100% specificity for predicting fluid responsiveness in critical care situations4, Starling can take out the guesswork of fluid assessment and provide reliable data to clinicians to make clinical decisions.

For these efforts and innovations introduced to the healthcare system, Baxter Healthcare was presented the Healthcare Technology Award in the recently concluded Hong Kong Business International Business Awards.

The annual programme honours first-rate international businesses in Hong Kong and awards outstanding foreign firms that stand out and can launch award-winning products and services.

After the initial launch of the three products in the Hong Kong market, Baxter Healthcare gained tremendous positive testimonials from customers. They received feedback that PrisMax helped alleviate ICU nurses’ workload; Evo IQ built a safety net to prevent medication errors, and Starling provided accurate data for personalised IV fluid therapy during an esophagus removal surgery.

Baxter is committed to continue providing aids to the healthcare sector, where digital transformation lays beneath as a solid foundation. Baxter utilize big data to drive Digital Health capacities and to enhance Customers Digital Experience, which leads to future digital therapy management solutions  such as the TrueVue Therapy Management on PrisMax and IQ Enterprise Connectivity Suite on Evo IQ.
 

  1.  References:Baxter – PrisMax Limited Controlled Distribution Report #ER6877 Rev A. Data on file. 2018
  2. Data on File. Baxter Healthcare Corporation. Evo IQ Human Factors Studies. 2018.
  3. Bentzer P, Griesdale D, Boyd J, et al. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA. 2016;316(12):1298-1309.
  4. Marik PE, Levitov A, Young A, Andrews L. The use of bioreactance and carotid Doppler to determine volume responsiveness and blood flow redistribution following passive leg raising in hemodynamically unstable patients. Chest. 2013;143(2):364-370

Follow the link for more news on

Join Hong Kong Business community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

Unemployment rate rises to 5.4% from February to April
The total number of unemployed people stands at 206,100.   The unemployment rate rose by 0.4 percentage points to 5.4%  from February to April, when compared to the January to March period.    Based on the data from the Census & Statistics Department (C&SD), the total number of unemployed people from February to April was 206,100, an increase of 17,600 from the preceding three-month period.   Meanwhile, the number of unemployed rose by around 25,000 to 142,000, translating to a rate of 3.8%.   With the increase in the number of jobless and underemployed individuals, total employment dropped to 3,559,200, whilst the labour force fell to 3,765,300.   The deterioration of Hong Kong’s labour market however should see an improvement in the coming months, according to Secretary for Labour & Welfare, Dr Law Chi-kwong.   The receding local epidemic situation and progressive relaxation of social distancing measures, the new round of Consumption Voucher Scheme, and Other relief measures including the 2022 Employment Support Scheme should help drive improvement in the employment sentiment, said the C&SD.  
Economy